Fractyl Logo
Revita logo

Addressing the root cause of T2D and obesity in the duodenum

T2D and obesity are driven by diet-induced gut dysfunction–a target at the core of the T2D and obesity pandemic

Tackling gut dysfunction at an early stage of disease might therefore be a promising treatment option to fight obesity and the resulting risks and complications.
Tschop and colleagues

Comp-1_3-1

REVITA IS DESIGNED FOR BROAD LARGE POPULATION ACCESSIBILITY

The Revita system comprises the Revita console that houses our proprietary technology and software and a single-use Revita catheter and single-use lineset.

< 1 hour procedure time
< 5 cases for proficiency

  • Straightforward procedure for patients and endoscopy teams
  • Designed to enable durable and repeatable metabolic improvement
  • Device and procedure optimized over 300 human procedures
  • 80+ patents issued worldwide covering methods, systems, and devices

Revita is now available in Germany

REVITA DEVELOPMENT PIPELINE IN T2D AND OBESITY

1. Revita has been granted Breakthrough Device designation for the hydrothermal ablation of the duodenal mucosa to improve glycemic control and eliminate insulin needs in T2D patients inadequately controlled on long-acting insulin; and CE mark obtained from EU and UK in 2016 for Revita for the improvement of glycemic control in patients with inadequately controlled T2D despite oral and/or injectable glucose lowering medications and/or long-acting insulin.
2. The Germany Real World Registry study is a post-market, clinical follow-up study in real-world patients with inadequately controlled T2D on at least one ADA.
3. The Revitalize-1 study is a pivotal study in patients with inadequately controlled T2D despite being on up to three ADAs and daily insulin.